Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down prior to trading on Wednesday. The stock had previously closed at $40.00, but opened at $37.70. Zealand Pharma A/S shares last traded at $37.70, with a volume of 334 shares changing hands.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Finally, Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold”.

Zealand Pharma A/S Trading Down 1.1%

The firm has a market cap of $2.70 billion, a price-to-earnings ratio of 6.25 and a beta of 0.95. The business has a fifty day moving average of $46.41 and a two-hundred day moving average of $46.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.